Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Precision Biosciences Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Biological Products, (No Diagnostic Substances)
No intraday reading yet this session.
Precision Biosciences Inc has 4 disclosed suppliers and 9 disclosed customers. Each one is named in an SEC filing, either Precision Biosciences Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“As a result, we have earned a cash payment of $7.5 million in proceeds, inclusive of $5.25 million cash and $2.25 million for the purchase of 201,504 shares of our common stock by TG Therapeutics at $11.17 per share.”
FILING10-K0001628280-26-017019cik 0001357874
“On October 31, 2025, we received an $8.0 million milestone payment from Imugene, comprised of $3.0 million in cash and $5.0 million in Imugene stock.”
FILING10-K0001628280-26-017019cik 0001357874
“In July 2024, we entered into an amended and restated loan and security agreement (the "2024 Loan and Security Agreement") with Banc of California pursuant to which Banc of California provided us with a term loan with a principal amount of $22.5 million (the "2024 Term Loan").”
FILING10-K0001628280-26-017019cik 0001357874
“Additionally on August 15, 2023, we and Imugene US entered into a license agreement (the "Imugene License Agreement"), pursuant to which we granted Imugene US certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize oncological applications of our allogeneic CAR T therapy, azer-cel, and up to three additional research product candidates directed to targets that Imugene US may nominate prior to the fifth anniversary of the effective date of the Imugene License Agreement, pursuant to the terms of the Imugene License Agreement.”
FILING10-K0001628280-26-017019cik 0001357874
“In July 2022, we received a $50.0 million upfront cash payment under the Novartis Agreement.”
FILING10-K0001628280-26-017019cik 0001357874
“On January 7, 2024, we entered into a license agreement (the "TG License Agreement") with TG Cell Therapy, Inc. ("TG Subsidiary") and its parent company TG Therapeutics, Inc. ("TG Parent" and, together with TG Subsidiary, "TG Therapeutics"), pursuant to which we granted TG Subsidiary certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize azercabtagene zapreleucel ("azer-cel") for autoimmune diseases and other indications outside of cancer.”
FILING10-K0001628280-26-017019cik 0001357874
“On January 7, 2024, we entered into a license agreement (the "TG License Agreement") with TG Cell Therapy, Inc. ("TG Subsidiary") and its parent company TG Therapeutics, Inc. ("TG Parent" and, together with TG Subsidiary, "TG Therapeutics"), pursuant to which we granted TG Subsidiary certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize azercabtagene zapreleucel ("azer-cel") for autoimmune diseases and other indications outside of cancer.”
FILING10-K0001628280-26-017019cik 0001357874
“Although Precision BioSciences, Inc. terminated its SPL agreement subsequent to its announced license of the Azercabtagene Zapreleucel (azer-cel) program to Imugene Limited and TG Therapeutics, Inc., both Imugene (USA), Inc. and TG Therapeutics, Inc. have since entered into SPL agreements with MaxCyte for azer-cel.”
FILING10-K0001104659-26-034557cik 0001287098disclosed by MXCT
“Additionally, we do not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from Cellectis.”
FILING10-K0001628280-26-017019cik 0001357874
“For example, our license agreement (the "Duke License") with Duke University ("Duke") imposes various payment, royalty and other obligations on us in order to maintain the license.”
FILING10-K0001628280-26-017019cik 0001357874
“Additionally contributing to the decrease in revenue was $9.5 million of revenue recognized under the TG License Agreement and the Caribou Biosciences, Inc. license agreement in the prior year.”
FILING10-K0001628280-26-017019cik 0001357874
“The decrease of $34.4 million in revenue during the year ended December 31, 2025 was primarily the result of $52.7 million of revenue recognized in the prior period related to the conclusion of our agreement with Prevail Therapeutics, which represented all remaining deferred revenue under that agreement.”
FILING10-K0001628280-26-017019cik 0001357874
“For example, we waived earned, but unpaid, milestone payments in connection with the termination of the development and commercial license agreement by and between Les Laboratoires Servier and Institut de Recherches Internationales, Servier (collectively "Servier").”
FILING10-K0001628280-26-017019cik 0001357874
Watchlist prices, news filtered to it, and its next report on your desk.
DTIL (Precision Biosciences Inc) has 4 disclosed suppliers and 9 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.